- Report
- December 2021
- 255 Pages
Global
From €2362EUR$2,598USD£2,022GBP
€3374EUR$3,712USD£2,889GBP
- Report
- September 2021
- 256 Pages
Global
From €2362EUR$2,598USD£2,022GBP
€3374EUR$3,712USD£2,889GBP
- Report
- September 2021
- 239 Pages
Global
From €2362EUR$2,598USD£2,022GBP
€3374EUR$3,712USD£2,889GBP
- Report
- August 2021
- 208 Pages
Global
From €2362EUR$2,598USD£2,022GBP
€3374EUR$3,712USD£2,889GBP
- Report
- November 2022
- 210 Pages
Global
From €2271EUR$2,499USD£1,945GBP
€3245EUR$3,570USD£2,778GBP
- Book
- July 2015
- 384 Pages
- Book
- April 2022
- 288 Pages
- Book
- December 2018
- 424 Pages
- Book
- December 2011
- 368 Pages
€2785EUR$3,282USD£2,468GBP

The Respiratory Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat respiratory diseases. These drugs are used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Commonly prescribed respiratory drugs include bronchodilators, corticosteroids, and antibiotics.
The Respiratory Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Novartis, and Boehringer Ingelheim. These companies are constantly researching and developing new drugs to treat respiratory diseases, as well as improving existing treatments. Show Less Read more